This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gohji, K. Articles by Nakajima, M. Search for Related Content PubMed PubMed Citation Articles by Gohji, K. Articles by Nakajima, M. Social Bookmarking                            What's this?

Independent Prognostic Value of Serum Hepatocyte Growth Factor in Bladder Cancer

From the Department of Urology, Osaka Medical College, Takatsuki; Department of Urology, Hyogo Medical Center for Adults, Akashi; Otsuka Pharmaceutical Co, Ltd, Tokushima; Department of Pathology, Kobe University School of Medicine, Kobe; and Biology Research, Tsukuba Research Institute Novartis Pharmaceuticals K.K., Tsukuba, Japan.

Address reprint requests to Kazuo Gohji, MD, PhD, Department of Urology, Osaka Medical College, 2–7 Daigakumatchi, Takatsuki, Osaka, 569-8686 Japan; email uro009{at}poh.osaka-med.ac.jp

PURPOSE: We retrospectively investigated whether the level of serum hepatocyte growth factor could predict the prognosis and extent of transitional-cell carcinoma of the urinary bladder.

PATIENTS AND METHODS: Serum samples were collected from 113 patients with bladder cancer and from 200 healthy controls. Of the 113 patients, 59 had superficial bladder cancer and 54 had muscle-invasive cancer. Thirteen bladder cancer tissues (eight superficial and five muscle-invasive) were also collected. The levels of hepatocyte growth factor in the serum and tissues of these individuals were measured by enzyme-linked immunoadsorbent assay using hepatocyte growth factor antibodies.

RESULTS: The levels of hepatocyte growth factor in the serum and tissues of patients with muscle-invasive cancer were significantly higher than those of patients with superficial bladder cancer (P < .0001 and P = .0054, respectively). The degree of elevation above the normal level of serum hepatocyte growth factor of the former (61.1%) was significantly higher than that of the latter (8.4%; P < .0001). The elevation was highest in patients with visceral metastasis (93.3%). Among patients with superficial bladder cancer, the overall survival rate of those with low levels of serum hepatocyte growth factor was significantly greater than that of those with high levels (P = .005). Among patients with minimally invasive bladder cancer, the disease-free and overall survival rates of those with high levels of serum hepatocyte growth factor were significantly lower than the same rates of those with low levels (P < .001 and P = .0028, respectively).

CONCLUSION: Our study suggests that the level of hepatocyte growth factor in serum could be a predictor of patient survival and extent of bladder cancer.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. McLarty, R. L.H. Bigelow, M. Smith, D. Elmajian, M. Ankem, and J. A. Cardelli Tea Polyphenols Decrease Serum Levels of Prostate-Specific Antigen, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor in Prostate Cancer Patients and Inhibit Production of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor In vitro Cancer Prevention Research, July 1, 2009; 2(7): 673 - 682. [Abstract] [Full Text] [PDF]

				F. KOGA, K. KIHARA, and L. NECKERS Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat-shock Protein 90 Anticancer Res, March 1, 2009; 29(3): 797 - 807. [Abstract] [Full Text] [PDF]

				C. Allen, S. Duffy, T. Teknos, M. Islam, Z. Chen, P. S. Albert, G. Wolf, and C. Van Waes Nuclear Factor-{kappa}B-Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma Clin. Cancer Res., June 1, 2007; 13(11): 3182 - 3190. [Abstract] [Full Text] [PDF]

				Y. Ren, B. Cao, S. Law, Y. Xie, P. Y. Lee, L. Cheung, Y. Chen, X. Huang, H. M. Chan, P. Zhao, et al. Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas Clin. Cancer Res., September 1, 2005; 11(17): 6190 - 6197. [Abstract] [Full Text] [PDF]

				S. Boorjian, S. K. Tickoo, N. P. Mongan, H. Yu, D. Bok, R. R. Rando, D. M. Nanus, D. S. Scherr, and L. J. Gudas Reduced Lecithin: Retinol Acyltransferase Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3429 - 3437. [Abstract] [Full Text] [PDF]

				P. Champelovier, A. Simon, C. Garrel, G. Levacher, V. Praloran, and D. Seigneurin Is Interferon {gamma} One Key of Metastatic Potential Increase in Human Bladder Carcinoma? Clin. Cancer Res., October 1, 2003; 9(12): 4562 - 4569. [Abstract] [Full Text] [PDF]

				S. Hara, H. Miyake, M. Fujisawa, H. Okada, S. Arakawa, S. Kamidono, and I. Hara Prognostic Variables in Patients Who Have Undergone Radical Cystectomy for Transitional Cell Carcinoma of the Bladder Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 399 - 402. [Abstract] [Full Text] [PDF]